BPC157 & TB500 Pen

Featured Product: BPC157 TB500 Blend (The “Wolverine Stack”)

SKU: PU-WOLVERINE-10MG
Purity: >99% (HPLC Tested)
Format: Lyophilized Powder (Sterile Vial)
Available Dosages: 5mg/5mg, 10mg/10mg, 15mg/15mg (High-Dose Protocol)

BPC157 TB500 Pen Peptide Product Overview

Introducing our premium BPC-157 and TB-500 blend, often referred to in research circles as the “Wolverine Stack.” This combination represents a synergistic approach to regenerative research, uniting the localized healing properties of BPC-157 with the systemic cellular repair capabilities of TB-500 . bpc157 tb500

Designed for advanced laboratory and research applications, this blend targets the fundamental pathways of tissue repair, angiogenesis (new blood vessel formation), and inflammation modulation. Whether investigating soft tissue recovery, gastrointestinal health, or general cellular regeneration, this peptide combination is a cornerstone of modern regenerative research .

BPC157 TB500 Pen Peptide Technical Specifications

Key Mechanisms of Action

BPC-157: The Local Healer
BPC-157 promotes tissue repair through several distinct pathways. Research indicates it upregulates Vascular Endothelial Growth Factor (VEGF) to promote angiogenesis, enhancing blood flow to damaged tissues. It also stimulates growth hormone receptor expression in tendon fibroblasts, accelerating collagen synthesis and improving the tensile strength of healing tissues .

TB-500: The Systemic Regulator
TB-500 is crucial for cellular migration and cytoskeletal organization. It binds to G-actin, facilitating cell movement necessary for wound repair. Additionally, it exhibits potent anti-inflammatory properties by modulating cytokine production and shifting macrophages toward an anti-inflammatory (M2) phenotype, which is essential for resolving chronic inflammation .

BPC157 TB500 Pen Peptide Research Applications & Indications

• Musculoskeletal Regeneration: Studied for tendon, ligament, and muscle repair. BPC-157 has shown efficacy in Achilles tendon healing models, improving biomechanical properties .

• Gastrointestinal Health: BPC-157 is particularly noted for its gastroprotective effects, promoting mucosal healing in models of inflammatory bowel disease and gastric ulcers .

• Cardiovascular Research: TB-500 is studied for preserving cardiac muscle viability following ischemic injury and promoting neovascularization .

• Neurological Support: Both peptides exhibit neuroprotective properties, with potential applications in neuronal survival and axonal regeneration .

BPC157 TB500 Pen Peptide Reconstitution & Dosage Protocol (For Research Purposes Only)

Proper reconstitution is critical for peptide integrity. Use sterile bacteriostatic water for injection.

Standard Reconstitution (5mg/5mg Vial):

• Add 2 mL of bacteriostatic water to the vial.

• Resulting concentration: 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500 .

BPC157 TB500 Pen Peptide Standard Research Dosage:

• Dose: 250–500 mcg of each peptide per injection.

• Volume Calculation: Using the above concentration, 0.1 mL (100 mcg) = 250 mcg of peptide. Draw 0.2 mL for a 500 mcg dose .

• Frequency: Typically administered once daily.

• Duration: Common research cycles last 4 to 6 weeks .

• Administration: Subcutaneous (Sub-Q) injection near the area of interest for localized research, or intramuscular for systemic distribution.

*Note: For high-dose protocols (e.g., 15mg/15mg vials), adjust reconstitution volumes accordingly to maintain precise dosing.*

---

2. Featured Product: Retatrutide (Triple Agonist Peptide)

SKU: PU-RETA-10MG
Purity: >99% (HPLC Tested)
Alias: LY-3437943, “Triple-G”

BPC157 TB500 Pen Peptide Product Overview

Retatrutide (LY-3437943) is a first-in-class triple hormone receptor agonist, representing the next evolution in metabolic research. Unlike single (GLP-1) or dual (GIP/GLP-1) agonists, Retatrutide uniquely targets GLP-1, GIP, and Glucagon (GCG) receptors simultaneously .

This triple-action mechanism offers a comprehensive approach to studying metabolic syndrome, obesity, and type 2 diabetes mellitus (T2DM) by combining appetite suppression with increased energy expenditure and enhanced fat metabolism .

Technical Specifications

Key Mechanisms of Action

1. GLP-1 (Glucagon-Like Peptide-1) Activation
Increases insulin secretion in a glucose-dependent manner, delays gastric emptying, and suppresses appetite by acting on the hypothalamus .

2. GIP (Glucose-dependent Insulinotropic Polypeptide) Activation
Enhances insulin secretion and improves fat metabolism. It works synergistically with GLP-1 to amplify satiety signals and metabolic control .

3. Glucagon (GCG) Activation
The distinguishing feature of Retatrutide. Glucagon agonism increases energy expenditure (basal metabolic rate), promotes lipolysis (fat breakdown), and reduces hepatic steatosis (fatty liver). The glucose-raising effect of glucagon is offset by the potent incretin action of GLP-1 and GIP, resulting in net glycemic improvement . BPC157 TB500 Pen Peptide

Research Applications & Clinical Findings

Obesity and Weight Management
Phase II clinical trials have demonstrated unprecedented efficacy. Subjects receiving the highest dose (12 mg weekly) achieved a mean weight reduction of 24.2% after 48 weeks—superior to existing dual agonists .

Type 2 Diabetes (T2DM)
Retatrutide significantly improves glycemic control, reducing HbA1c levels and fasting glucose. Notably, in the Phase II trial, 100% of participants with prediabetes in the 8mg and 12mg groups reverted to normal glycemic status .

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Retatrutide dramatically reduces liver fat content. In a substudy, the 12mg dose reduced liver fat by an average of 86%, with nearly 86% of participants achieving total resolution of excess liver fat (<5%) . BPC157 TB500 Pen Peptide

Reconstitution & Dosing Protocol (For Research Purposes Only)

Retatrutide is typically administered via subcutaneous injection once weekly in research protocols.

Standard Reconstitution (10mg Vial):

• Add 2 mL of bacteriostatic water to the vial.

• Resulting concentration: 5 mg/mL.

Research Dosage Protocol (Titration Schedule):
To minimize gastrointestinal side effects, researchers often follow a dose-escalation schedule similar to clinical trials :

Note: Always start at the lowest dose to assess tolerance. These doses reflect clinical research protocols and are intended for laboratory use only.

---

Why Choose PeptidesUnit.com?

• Verified Purity: Every batch is tested by independent third-party labs for purity and mass verification (>99%).

• Lyophilized Stability: Shipped in lyophilized (freeze-dried) powder form to ensure maximum stability during transit.

• Discreet Packaging: Shipped in secure, temperature-controlled packaging.

• Research Focus: We cater strictly to researchers and laboratories. All products are intended for in-vitro research and laboratory use only.

---

BPC157 TB500 Pen Peptide Legal & Safety Disclaimer

For Research Use Only. Not for human consumption or clinical therapeutic use. Not for use in food or cosmetics. Not for veterinary use. This product is not a drug, medical device, or dietary supplement. By purchasing, the buyer assumes all responsibility for the use of this product. PeptidesUnit.com does not condone the use of these products in violation of any laws, regulations, or for non-research purposes. BPC157 TB500 peptides